Rowena Korobkin
Neurology with Special Qualifications in Child Neurology · Sonoma, CANPI 1518919729
Payments from drug & device makers
Across 255 payments — averaging $22.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Livanova USA, Inc.$1K
- SK Life Science, Inc.$1K
- Eisai Inc.$717
- Jazz Pharmaceuticals Inc.$493
- Catalyst Pharmaceuticals, Inc.$446
- plus $477 from 5 others
What the payments were for
- Travel & lodging$3917%
- Food & beverage$5,45393%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 92 | $1,578 |
| Livanova USA, Inc. | 22 | $1,099 |
| SK Life Science, Inc. | 42 | $1,035 |
| Eisai Inc. | 42 | $717 |
| Jazz Pharmaceuticals Inc. | 10 | $493 |
| Catalyst Pharmaceuticals, Inc. | 20 | $446 |
| Greenwich Biosciences, Inc. | 7 | $229 |
| Sunovion Pharmaceuticals Inc. | 15 | $140 |
| Neurelis, Inc. | 2 | $55 |
| GSK | 2 | $33 |
| Merck | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$868
- Epidiolex$150
- XCOPRI$118
How this compares
$5,844 in reported general payments places this provider in the 60th percentile of 216 neurology with special qualifications in child neurology providers in California.
See all neurology with special qualifications in child neurology providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 94 | $108,700 |
| FycompaPerampanel | 64 | $68,499 |
| BriviactBrivaracetam | 25 | $37,682 |
| Levetiracetam | 196 | $7,068 |
| Lamotrigine OdtLamotrigine | 12 | $5,877 |
| Lacosamide | 39 | $4,890 |
| Divalproex Sodium | 63 | $4,803 |
| Carbamazepine | 25 | $2,338 |
| Carbamazepine ErCarbamazepine | 23 | $2,266 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $1,514 |
| Topiramate | 72 | $1,321 |
| Lamotrigine | 80 | $1,292 |
| Clobazam | 29 | $1,200 |
| Zonisamide | 30 | $1,181 |
| Gabapentin | 26 | $1,006 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SK Life Science, Inc.Xcopri | $1,035 | $108,70094 claims |
| Eisai Inc.Fycompa | $717 | $68,49964 claims |
| UCB, Inc.Briviact | $1,578 | $37,68225 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 216 neurology with special qualifications in child neurology providers in California.
Other neurology with special qualifications in child neurology in Sonoma
- Sabine MuellerSan Francisco$17.5M
- Joseph SullivanSan Francisco$1.7M
- Rajsekar RajaramanLos Angeles$1.5M
- Jonathan SantoroPalo Alto$1.5M
- Michelle MonjePalo Alto$1.3M
- Jay DesaiLos Angeles$1.2M
- Richard HaasSan Diego$1.2M
- Leigh Maria Ramos PlattLos Angeles$981K
- Agnes ChenTorrance$792K
- Wendy MitchellLos Angeles$749K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.